Mucommune LLC
Durham, NC
- UEI
- NWVPL2L4JMN8
- CAGE
- 7C3Q6
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 1106 Crested Jay Dr, Durham, NC 27707, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $6,453,153 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Mucommune LLC is a biopharmaceutical company based in Durham, North Carolina, specializing in innovative medical technologies across reproductive health, infectious disease prevention, and targeted antibody therapies. The company is a small, for-profit limited liability company registered in SAM.gov, focusing on developing advanced biotechnological solutions for complex medical challenges. Through federal contract and grant awards, Mucommune demonstrates expertise in developing cutting-edge medical interventions, particularly in areas involving monoclonal antibodies, intravaginal delivery systems, and novel therapeutic approaches.
Regarding federal contract awards, Mucommune LLC has secured a significant contract from the National Institute of Allergy and Infectious Diseases (NIAID) under the Small Business Innovation Research (SBIR) program. The $2,355,605 Firm Fixed Price contract focuses on developing a sustained release mechanism for VRC07 from a capsule-intravaginal ring to prevent HIV transmission. The contract is set aside for small businesses and has a performance period through June 30, 2028, highlighting the company's specialized research capabilities in developing targeted intervention strategies for infectious diseases.
In federal grant awards, Mucommune has received multiple project grants from various National Institutes of Health agencies, focusing on innovative medical research. These grants include developing in vivo-engineered CAR-T cells for cancer immunotherapy from the National Cancer Institute, creating non-hormonal contraceptive products from the National Institute of Child Health and Human Development, and designing interventions for conditions like bacterial vaginosis from the National Institute of Allergy and Infectious Diseases. The grants range from $310,136 to $1,146,618 and cover research areas such as cellular immunotherapy for pancreatic and ovarian cancers, anti-sperm antibody-based contraception, lactic acid-releasing intravaginal rings, and addressing challenges with pegylated drug therapies. Each grant demonstrates the company's commitment to developing sophisticated, targeted medical solutions across multiple therapeutic domains.
Quick answers
Is Mucommune LLC registered in SAM.gov?
Yes. Mucommune LLC's SAM.gov registration is active through July 25, 2027.
How much has Mucommune LLC received in federal contracts?
Federal contracts obligated $6,453,153 to Mucommune LLC in fiscal year 2025.
How does Mucommune LLC rank among federal contractors?
Mucommune LLC ranked #45 in PSC AN13 in FY2025.
What is Mucommune LLC's most recent federal award?
Mucommune LLC's most recent federal grant award is Sbir: in vivo engineering of multifaceted B7H3.car-t cells for cellular immunotherapy of pancreatic ductal… (R44CA310402), from National Cancer Institute (NIH), on September 16, 2025.
On GovTribe
See Mucommune LLC's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors